非那雄胺市场机会、成长驱动因素、产业趋势分析及预测（2026-2035年）

2025 年全球非那雄胺市值为 1.308 亿美元，预计到 2035 年将以 2.4% 的复合年增长率增长至 1.658 亿美元。

儘管面临同类药物的竞争以及低价仿製药的压力，非那雄胺仍保持稳定成长。这一增长主要得益于新核准适应症的出现、医学界更广泛的认可以及处方率的提高。虽然美国、加拿大和西欧等成熟市场已接近饱和，成长有限，但东亚和印度的需求仍持续上升。收入水准的提高、个人形象支出的增加、对良性前列腺增生（BPH）和雄激素性脱髮的认识不断提高以及专科医疗服务的可及性改善等因素，都在推动这一趋势。预计这种强劲且持续的需求将在未来几年内保持，从而支撑市场的长期稳定。

2025年，雄性秃市占率为42.6%，预计到2035年将以2%的复合年增长率成长。非那雄胺主要用于治疗良性前列腺增生症（BPH）和雄性秃。 BPH多见于老年男性，形成了一个稳定的患者群体，主要透过泌尿科和初级保健进行管理。男性型秃髮影响较年轻的患者，推动了北美、欧洲和亚洲地区皮肤科、远端皮肤科和直接面向消费者的管道对非那雄胺的推广应用。

到2025年，零售和社区通路市场占有率将达到61%，预计到2035年将以3.4%的复合年增长率成长。处方非那雄胺仍主要透过传统零售和社区管道销售，包括独立药房和连锁药局。医院药局为住院治疗和专科医生主导的治疗提供支持，尤其是在泌尿科领域；而城市地区的皮肤科和毛髮科诊所通常是主要的处方机构和决策者。

2025年北美非那雄胺市场规模为3,410万美元，预计2035年将达4,350万美元。该地区的增长得益于良性前列腺增生症（BPH）处方量的稳定、仿製药的广泛普及、较高的诊断率、强大的泌尿科和皮肤科医疗网络，以及远程皮肤科在脱髮治疗中的日益普及。然而，由于健保政策和仿製药的竞争，价格增长仍然受到限制。

目录

第一章：方法论与范围

第二章：执行概要

第三章：行业洞察

• 产业生态系分析
  • 供应商格局
  • 利润率
  • 每个阶段的价值增加
  • 影响价值链的因素
  • 中断
• 产业影响因素
  • 成长驱动因素
    • 男性老化族群中良性前列腺增生症负担日益加重
    • 越来越注重脱髮疗程的美容效果
    • 扩大低成本仿製药的取得途径
  • 产业陷阱与挑战
    • 安全隐患与黑盒子式警告
    • 强大的仿製药竞争和报销压力
  • 市场机会
    • 拓展数位化处方和电子药局管道
    • 米诺地尔与新药的合併治疗方案
• 成长潜力分析
• 监管环境
  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东和非洲
• 波特的分析
• PESTEL 分析
• 价格趋势
  • 按地区
  • 透过治疗应用
• 未来市场趋势
• 技术与创新格局
  • 当前技术趋势
  • 新兴技术
• 专利格局
• 贸易统计（HS编码）（註：仅提供重点国家的贸易统计资料）
  • 主要进口国
  • 主要出口国
• 永续性和环境方面
  • 永续实践
  • 减少废弃物策略
  • 生产中的能源效率
  • 环保倡议
• 碳足迹考量

第四章：竞争格局

• 介绍
• 公司市占率分析
  • 按地区
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • MEA
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 关键进展
  • 併购
  • 合作伙伴关係与合作
  • 新产品发布
  • 扩张计划

第五章：市场估计与预测：依治疗应用划分，2022-2035年

• 雄性秃（雄性秃）
• 良性摄护腺增生（BPH）
• 女性型秃头（部分病例）
• 多毛症和其他雄性激素介导的疾病
• 其他的

第六章：市场估算与预测：依剂量强度划分，2022-2035年

• 口服 1 毫克
• 口服 5 毫克
• 局部用量≤0.1%
• 局部用药 > 0.1% 至 0.25%
• 局部用药浓度 > 0.25% 至 0.5% 以上

第七章：市场估算与预测：依配销通路划分，2022-2035年

• 零售和社区通路
  • 社区药房
  • 连锁药局
  • 网上药局（合法持牌）
• 制度管道
  • 医院药房
  • 专科诊所（泌尿科、皮肤科、毛髮科）
  • 直接面向消费者（DTC）模式
• 其他的

第八章：市场估算与预测：依应用领域划分，2022-2035年

• 摄护腺治疗
  • 摄护腺增生
  • 摄护腺癌
  • 荷尔蒙疗法（跨性别女性）
• 头髮护理
  • 头皮脱髮
  • 毛髮过多

第九章：市场估计与预测：依地区划分，2022-2035年

• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 欧洲其他地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地区
• 中东和非洲
  • 沙乌地阿拉伯
  • 南非
  • 阿联酋
  • 中东和非洲其他地区

第十章：公司简介

• Merck & Co., Inc. (MSD)
• Teva Pharmaceutical Industries Ltd.
• Sandoz (Novartis division)
• Mylan (Viatris Inc.)
• Sun Pharmaceutical Industries Ltd.
• Dr. Reddy's Laboratories Ltd.
• Cipla Ltd.
• Aurobindo Pharma Ltd.
• Lupin Ltd.
• Torrent Pharmaceuticals Ltd.
• Hikma Pharmaceuticals plc
• Apotex Inc.

The Global Finasteride Market was valued at USD 130.8 million in 2025 and is estimated to grow at a CAGR of 2.4% to reach USD 165.8 million by 2035.

Despite facing competition from other drugs in its class and pressure from lower-priced generics, finasteride continues to experience steady growth. This expansion is driven by newly approved indications, broader acceptance in the medical community, and increasing prescription rates. While mature markets in the US, Canada, and Western Europe have reached near-saturation, showing limited growth, demand in Eastern Asia and India continues to rise. Factors such as higher income levels, increased spending on personal appearance, growing awareness of benign prostatic hyperplasia (BPH) and androgenetic alopecia, and better access to specialist care are fueling this trend. This strong and sustained demand is expected to continue over the coming years, supporting long-term market stability.

The androgenetic alopecia segment held 42.6% share in 2025 and is expected to grow at a CAGR of 2% through 2035. Finasteride is primarily prescribed for BPH and androgenetic alopecia. BPH is prevalent among older men, creating a stable patient base primarily managed through urology and primary care. Male pattern hair loss, affecting younger patients, has fueled adoption through dermatology, tele-dermatology, and direct-to-consumer programs across North America, Europe, and Asia.

The retail and community channel segment held a 61% share in 2025 and is anticipated to grow at a CAGR of 3.4% through 2035. Prescription finasteride continues to be dispensed mainly via traditional retail and community channels, including independent pharmacies and chain drug stores. Hospital pharmacies support inpatient care and specialist-initiated therapy, particularly in urology, while dermatology and trichology clinics in urban areas often serve as primary prescribers and influencers.

North America Finasteride Market accounted for USD 34.1 million in 2025, and is expected to reach USD 43.5 million by 2035. Growth in the region is supported by stable BPH prescriptions, widespread generic availability, high diagnostic rates, robust urology and dermatology networks, and the expanding use of tele-dermatology for hair loss. Price growth, however, remains constrained due to reimbursement policies and generic competition.

Key players operating in the Global Finasteride Market include Merck & Co., Inc. (MSD), Teva Pharmaceutical Industries Ltd., Sandoz (Novartis division), Mylan (Viatris Inc.), Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Cipla Ltd., Aurobindo Pharma Ltd., Lupin Ltd., Torrent Pharmaceuticals Ltd., Hikma Pharmaceuticals plc, and Apotex Inc. Companies in the Global Finasteride Market are adopting multiple strategies to strengthen their presence and expand market share. They are launching new generic formulations to increase accessibility and compete on price while maintaining quality standards. Strategic partnerships and licensing agreements with regional manufacturers help widen distribution networks and penetrate emerging markets. Investments in marketing, physician education, and telemedicine platforms enhance awareness and adoption, particularly for androgenetic alopecia treatment.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Data mining sources
  • 1.3.1 Global
  • 1.3.2 Regional/Country
• 1.4 Base estimates and calculations
  • 1.4.1 Base year calculation
  • 1.4.2 Key trends for market estimation
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
• 1.6 Forecast model
• 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis
• 2.2 Key market trends
  • 2.2.1 Regional
  • 2.2.2 Therapeutic application
  • 2.2.3 Dosage strength
  • 2.2.4 Distribution channel
  • 2.2.5 Application
• 2.3 TAM Analysis, 2026-2035
• 2.4 CXO perspectives: Strategic imperatives
  • 2.4.1 Executive decision points
  • 2.4.2 Critical success factors
• 2.5 Future Outlook and Strategic Recommendations

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
  • 3.1.1 Supplier landscape
  • 3.1.2 Profit margin
  • 3.1.3 Value addition at each stage
  • 3.1.4 Factor affecting the value chain
  • 3.1.5 Disruptions
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising BPH burden in aging male populations
    • 3.2.1.2 Increasing aesthetic focus on hair-loss treatment
    • 3.2.1.3 Widening access to low-cost generics
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Safety concerns and black-box style warnings
    • 3.2.2.2 Strong generic competition and reimbursement pressure
  • 3.2.3 Market opportunities
    • 3.2.3.1 Expansion of digital prescribing and e-pharmacy channels
    • 3.2.3.2 Combination regimens with minoxidil and new agents
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
  • 3.4.1 North America
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
  • 3.4.4 Latin America
  • 3.4.5 Middle East & Africa
• 3.5 Porter's analysis
• 3.6 PESTEL analysis
• 3.7 Price trends
  • 3.7.1 By region
  • 3.7.2 By Therapeutic application
• 3.8 Future market trends
• 3.9 Technology and Innovation landscape
  • 3.9.1 Current technological trends
  • 3.9.2 Emerging technologies
• 3.10 Patent Landscape
• 3.11 Trade statistics (HS code) (Note: the trade statistics will be provided for key countries only)
  • 3.11.1 Major importing countries
  • 3.11.2 Major exporting countries
• 3.12 Sustainability and environmental aspects
  • 3.12.1 Sustainable practices
  • 3.12.2 Waste reduction strategies
  • 3.12.3 Energy efficiency in production
  • 3.12.4 Eco-friendly initiatives
• 3.13 Carbon footprint consideration

Chapter 4 Competitive Landscape, 2025

• 4.1 Introduction
• 4.2 Company market share analysis
  • 4.2.1 By region
    • 4.2.1.1 North America
    • 4.2.1.2 Europe
    • 4.2.1.3 Asia Pacific
    • 4.2.1.4 LATAM
    • 4.2.1.5 MEA
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Mergers & acquisitions
  • 4.6.2 Partnerships & collaborations
  • 4.6.3 New Product Launches
  • 4.6.4 Expansion Plans

Chapter 5 Market Estimates and Forecast, By Therapeutic Application, 2022-2035 (USD Million) (Kilo Tons)

• 5.1 Key trends
• 5.2 Androgenetic alopecia (male pattern hair loss)
• 5.3 Benign prostatic hyperplasia (BPH)
• 5.4 Female pattern hair loss (selected cases)
• 5.5 Hirsutism and other androgen-mediated conditions
• 5.6 Others

Chapter 6 Market Estimates and Forecast, By Dosage Strength, 2022-2035 (USD Million) (Kilo Tons)

• 6.1 Key trends
• 6.2 Oral 1 mg
• 6.3 Oral 5 mg
• 6.4 Topical ≤ 0.1%
• 6.5 Topical > 0.1% to 0.25%
• 6.6 Topical > 0.25% to 0.5% and above

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2022-2035 (USD Million) (Kilo Tons)

• 7.1 Key trends
• 7.2 Retail and community channels
  • 7.2.1 Community pharmacies
  • 7.2.2 Chain drugstores
  • 7.2.3 Online pharmacies (legally licensed)
• 7.3 Institutional channels
  • 7.3.1 Hospital pharmacies
  • 7.3.2 Specialty clinics (urology, dermatology, trichology)
  • 7.3.3 Direct-to-consumer (DTC) models
• 7.4 Others

Chapter 8 Market Estimates and Forecast, By Application, 2022-2035 (USD Million) (Kilo Tons)

• 8.1 Key trends
• 8.2 Prostate Treatment
  • 8.2.1 Prostate Enlargement
  • 8.2.2 Prostate Cancer
  • 8.2.3 Hormone therapy (Transgender Women)
• 8.3 Hair Treatment
  • 8.3.1 Scalp Hair Loss
  • 8.3.2 Excessive Hair Growth

Chapter 9 Market Estimates and Forecast, By Region, 2022-2035 (USD Million) (Kilo Tons)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 India
  • 9.4.3 Japan
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
  • 9.5.4 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 South Africa
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 Merck & Co., Inc. (MSD)
• 10.2 Teva Pharmaceutical Industries Ltd.
• 10.3 Sandoz (Novartis division)
• 10.4 Mylan (Viatris Inc.)
• 10.5 Sun Pharmaceutical Industries Ltd.
• 10.6 Dr. Reddy’s Laboratories Ltd.
• 10.7 Cipla Ltd.
• 10.8 Aurobindo Pharma Ltd.
• 10.9 Lupin Ltd.
• 10.10 Torrent Pharmaceuticals Ltd.
• 10.11 Hikma Pharmaceuticals plc
• 10.12 Apotex Inc.